Personal information

Other IDs

Scopus Author ID: 56497440600

Activities

Collapse all

Employment (2)

The University of Texas MD Anderson Cancer Center: Houston, TX, US

2020-07-01 to present
Employment
Source: Self-asserted source
Max Gordon

Oregon Health and Science University: Portland, OR, US

2014-07-01 to present (Internal Medicine)
Employment
Source: Self-asserted source
Max Gordon

Education and qualifications (1)

University of Minnesota: MN, MN, US

2010-06-01 to 2014-06-01 | MD
Education
Source: Self-asserted source
Max Gordon

Works (19)

Multi-Center Analysis of Practice Patterns and Outcomes of Younger and Older Patients with Mantle Cell Lymphoma in the Rituximab Era.

American journal of hematology
2021-07-29 | Journal article
DOI: 10.1002/ajh.26306
PMID: 34324220
Source: Self-asserted source
Max Gordon

Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study.

Haematologica
2021-07-01 | Journal article
DOI: 10.3324/haematol.2020.270876
PMID: 33538152
Source: Self-asserted source
Max Gordon

The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model.

Clinical cancer research : an official journal of the American Association for Cancer Research
2021-06-24 | Journal article
DOI: 10.1158/1078-0432.ccr-20-3993
PMID: 34168050
Source: Self-asserted source
Max Gordon

Intensive induction regimens after deferring initial therapy for mantle cell lymphoma are not associated with improved survival.

European journal of haematology
2021-06-17 | Journal article
DOI: 10.1111/ejh.13649
PMID: 33973276
Source: Self-asserted source
Max Gordon

The evolving role of Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia.

Therapeutic advances in hematology
2021-01-30 | Journal article
DOI: 10.1177/2040620721989588
PMID: 33796237
PMC: PMC7970705
Source: Self-asserted source
Max Gordon

Comorbidities Predict Inferior Survival in Patients Receiving Chimeric Antigen Receptor T Cell Therapy for Diffuse Large B Cell Lymphoma: A Multicenter Analysis.

Transplantation and cellular therapy
2020-09-29 | Journal article
DOI: 10.1016/j.bbmt.2020.09.028
PMID: 33002640
Source: Self-asserted source
Max Gordon

Medical comorbidities in patients with chronic lymphocytic leukaemia treated with idelalisib: analysis of two large randomised clinical trials.

British journal of haematology
2020-06-29 | Journal article
DOI: 10.1111/bjh.16879
PMID: 32599655
Source: Self-asserted source
Max Gordon

A simplified prognostic index for chronic lymphocytic leukemia treated with ibrutinib: Results from a multicenter retrospective cohort study.

Leukemia research
2020-01-21 | Journal article
DOI: 10.1016/j.leukres.2020.106302
PMID: 31982152
Source: Self-asserted source
Max Gordon

Refractory Autoimmune Cytopenias Treated With Venetoclax.

HemaSphere
2019-06-04 | Journal article
DOI: 10.1097/hs9.0000000000000202
PMID: 31723832
PMC: PMC6746017
Source: Self-asserted source
Max Gordon

Deferred treatment is a safe and viable option for selected patients with mantle cell lymphoma.

Leukemia & lymphoma
2018-06-18 | Journal article
DOI: 10.1080/10428194.2018.1455973
PMID: 29912594
PMC: PMC6360945
Source: Self-asserted source
Max Gordon

Comorbidities predict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinib.

Cancer
2018-05-24 | Journal article
DOI: 10.1002/cncr.31554
PMID: 29797667
Source: Self-asserted source
Max Gordon

Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy.

Cancer
2018-03-26 | Journal article
DOI: 10.1002/cncr.31328
PMID: 29579328
PMC: PMC5992038
Source: Self-asserted source
Max Gordon

Bendamustine hydrochloride in patients with B-cell malignancies who have comorbidities–is there an optimal dose?

Expert Review of Hematology
2017 | Journal article
DOI: 10.1080/17474086.2017.1350166
EID:

2-s2.0-85026438242
Contributors: Gordon, M.J.; Lewis, L.D.; Brown, J.R.; Danilov, A.V.
Source: Self-asserted source
Max Gordon via Scopus - Elsevier

CPX-351 exhibits potent and direct ex vivo cytotoxicity against AML blasts with enhanced efficacy for cells harboring the FLT3-ITD mutation

Leukemia Research
2017 | Journal article
DOI: 10.1016/j.leukres.2016.12.002
EID:

2-s2.0-85007018242
Contributors: Gordon, M.J.; Tardi, P.; Loriaux, M.M.; Spurgeon, S.E.; Traer, E.; Kovacsovics, T.; Mayer, L.D.; Tyner, J.W.
Source: Self-asserted source
Max Gordon via Scopus - Elsevier

Cardiac non-Hodgkin's lymphoma: clinical characteristics and trends in survival

European Journal of Haematology
2016 | Journal article
DOI: 10.1111/ejh.12751
EID:

2-s2.0-84962787578
Contributors: Gordon, M.J.; Danilova, O.; Spurgeon, S.; Danilov, A.V.
Source: Self-asserted source
Max Gordon via Scopus - Elsevier

Ibrutinib is an effective treatment for B-cell prolymphocytic leukaemia

British Journal of Haematology
2016 | Journal article
DOI: 10.1111/bjh.14224
EID:

2-s2.0-84994075785
Contributors: Gordon, M.J.; Raess, P.W.; Young, K.; Spurgeon, S.E.F.; Danilov, A.V.
Source: Self-asserted source
Max Gordon via Scopus - Elsevier

Safety and effectiveness of enzalutamide in men with metastatic, castration-resistant prostate cancer

Expert Opinion on Pharmacotherapy
2015 | Journal article
DOI: 10.1517/14656566.2015.1016911
EID:

2-s2.0-84924351297
Contributors: Graff, J.N.; Gordon, M.J.; Beer, T.M.
Source: Self-asserted source
Max Gordon via Scopus - Elsevier

An unusual case of Ewing sarcoma: A middle-aged woman with multiple recurrences over 36 years

Journal of Pediatric Hematology/Oncology
2014 | Journal article
EID:

2-s2.0-84910119429
Contributors: Gordon, M.J.; Carlosmanivel, J.; Cheng, E.Y.; Skubitz, K.M.
Source: Self-asserted source
Max Gordon via Scopus - Elsevier

Lymphoma of the hands in a patient with rheumatoid arthritis: Case report

Journal of Hand Surgery
2014 | Journal article
DOI: 10.1016/j.jhsa.2014.01.034
EID:

2-s2.0-84897146609
Contributors: Gordon, M.J.; Peterson, B.A.; Skubitz, K.M.
Source: Self-asserted source
Max Gordon via Scopus - Elsevier

Peer review (1 review for 1 publication/grant)

Review activity for Targeted oncology. (1)
How many people are using ORCID?